Next Article in Journal
Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus
Next Article in Special Issue
Vaccination with Tozimameran Induces T-Cell Activation, but Not Senescent or Exhaustive Alterations, in Kidney Transplant Recipients
Previous Article in Journal
Immunogenicity and Protective Efficacy of Aerosolized Live-Attenuated Yellow Fever 17D Vaccine in Mice
Previous Article in Special Issue
Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus

by
Beatrice Bălăceanu-Gurău
1,2,*,
Adrian Dumitrascu
3,
Călin Giurcăneanu
1,2,
Raluca Tatar
4,5,*,
Cristian-Dorin Gurău
6 and
Olguța Anca Orzan
1,2
1
Department of Oncologic Dermatology, “Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2
Clinic of Dermatology, “Elias” Emergency University Hospital, 011461 Bucharest, Romania
3
Division of Hospital Internal Medicine, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, USA
4
Department of Plastic Reconstructive Surgery and Burns, “Grigore Alexandrescu” Clinical Emergency Hospital for Children, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
5
Department of Plastic Reconstructive Surgery and Burns, “Grigore Alexandrescu” Clinical Emergency Hospital for Children, 010621 Bucharest, Romania
6
Orthopedics and Traumatology Clinic, Clinical Emergency Hospital, 014451 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
Vaccines 2024, 12(8), 857; https://doi.org/10.3390/vaccines12080857
Submission received: 9 June 2024 / Revised: 19 July 2024 / Accepted: 27 July 2024 / Published: 30 July 2024
(This article belongs to the Special Issue 2nd Edition: Safety and Autoimmune Response to SARS-CoV-2 Vaccination)

Abstract

Autoimmune bullous diseases (AIBDs) are characterized by the formation of vesicles, bullous lesions, and mucosal erosions. The autoantibodies target the cellular anchoring structures from the surface of epidermal keratinocyte named desmosomes, leading to a loss of cellular cohesion named acantholysis. AIBDs are classified into intraepidermal or subepidermal types based on clinical features, histological characteristics, and immunofluorescence patterns. Pemphigus foliaceus (PF) is an acquired, rare, autoimmune skin condition associated with autoantibodies that specifically target desmoglein-1, leading to a clinical presentation characterized by delicate cutaneous blisters, typically sparing the mucous membranes. Several factors, including genetic predisposition, environmental triggers, malignancies, medication use, and vaccination (for influenza, hepatitis B, rabies, tetanus, and more recently, severe acute respiratory syndrome Coronavirus 2 known as SARS-CoV-2), can potentially trigger the onset of pemphigus. With the advent of vaccines playing a pivotal role in combatting the 2019 coronavirus disease (COVID-19), extensive research has been conducted globally to ascertain their efficacy and potential cutaneous adverse effects. While reports of AIBDs post-COVID-19 vaccination exist in the medical literature, instances of PF following vaccination have been less commonly reported worldwide. The disease’s pathophysiology is likely attributed to the resemblance between the ribonucleic acid (RNA) antigen present in these vaccines and cellular nuclear matter. The protein produced by the BNT-162b2 messenger ribonucleic acid (mRNA) vaccine includes immunogenic epitopes that could potentially trigger autoimmune phenomena in predisposed individuals through several mechanisms, including molecular mimicry, the activation of pattern recognition receptors, the polyclonal stimulation of B cells, type I interferon production, and autoinflammation. In this review, we present a comprehensive examination of the existing literature regarding the relationship between COVID-19 and PF, delving into their intricate interactions. This exploration improves the understanding of both pemphigus and mRNA vaccine mechanisms, highlighting the importance of close monitoring for PF post-immunization.
Keywords: coronavirus disease; COVID-19 vaccination; mRNA vaccines; autoimmunity; autoimmune bullous diseases; pemphigus foliaceus coronavirus disease; COVID-19 vaccination; mRNA vaccines; autoimmunity; autoimmune bullous diseases; pemphigus foliaceus

Share and Cite

MDPI and ACS Style

Bălăceanu-Gurău, B.; Dumitrascu, A.; Giurcăneanu, C.; Tatar, R.; Gurău, C.-D.; Orzan, O.A. A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus. Vaccines 2024, 12, 857. https://doi.org/10.3390/vaccines12080857

AMA Style

Bălăceanu-Gurău B, Dumitrascu A, Giurcăneanu C, Tatar R, Gurău C-D, Orzan OA. A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus. Vaccines. 2024; 12(8):857. https://doi.org/10.3390/vaccines12080857

Chicago/Turabian Style

Bălăceanu-Gurău, Beatrice, Adrian Dumitrascu, Călin Giurcăneanu, Raluca Tatar, Cristian-Dorin Gurău, and Olguța Anca Orzan. 2024. "A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus" Vaccines 12, no. 8: 857. https://doi.org/10.3390/vaccines12080857

APA Style

Bălăceanu-Gurău, B., Dumitrascu, A., Giurcăneanu, C., Tatar, R., Gurău, C.-D., & Orzan, O. A. (2024). A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus. Vaccines, 12(8), 857. https://doi.org/10.3390/vaccines12080857

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop